TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02505620

Intervention type: PROCEDURE
Intervention: Treatment of OSAS with CPAP mask
Description: Interventional treatment addresses the treatment with a CPAP (continuous positive airway pressure) mask in oder to open patients upper airway obstructive permanently while sleep.

Intervention type: PROCEDURE
Intervention: Surgical Treatment with multilevel operation
Description: Surgical treatment addresses a surgical multilevel anti-obstructive operation in order to eliminate upper airway obstruction permanently.
Study: NCT01818076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Botulinum toxin type A, Dose A applied to the lateral canthal area
Study: NCT01227772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OTSGC-A24
Description: OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OTSGC-A24
Description: OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OTSGC-A24
Description: OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
Study: NCT02164747

Intervention type: DEVICE
Intervention: Residents of nursing homes with telemedicine after implementation of telemedicine
Study: NCT04136392

Intervention type: DEVICE
Intervention: ABIOMED, Inc. hemodynamic support devices
Description: ABIOMED, Inc. hemodynamic support technology are the smallest and least invasive percutaneous ventricular support blood pumps available on the market. They are routinely used in clinical practice in a variety of clinical scenarios to support patients in prophylactic or emergent settings.
Study: NCT03809442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Ketamine
Description: Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Tramadol
Description: Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Midazolam
Description: Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Dexmedetomidine
Description: Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kg dexmedetomidine (8mL per incision) (Dexmedetomidine group).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Dexamethasone
Description: Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg.
Study: NCT04382833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOT APPLICATION
Description: HOT APPLICATION

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MASSAGE
Study: NCT01172847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir [Tamiflu]
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir [Tamiflu]
Description: multiple oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rimantadine
Description: multiple oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimantadine
Description: multiple oral doses
Study: NCT01702701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: montelukast 10mg po pill q day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: fluticasone 440mcg po q bid x 12 weeks
Study: NCT03742609

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ii) the reminder
Description: Participants assigned to the prompt group were received instruction to use their hearing aid box as a physical prompt to remind participants to use their hearing aid(s)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ii) written behavioural plan
Description: Participants assigned to this group were received instruction to create at least one written plan for hearing aid use. Specifically, participants were asked to plan where and when to use their hearing aid(s).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iv) all materials
Description: i) provision of written information regarding consequences of using a hearing aid and not using a hearing aid, ii) the provision of a physical prompt for the purpose of prompting or cueing the behavior (hearing aid use) development, and iii) creation of a written behavioural plan for hearing aid use.
Study: NCT02408939

Intervention type: DRUG
Intervention: Stress-dose hydrocortisone
Description: Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
Study: NCT03852303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: evaluate effect of ivermectin on frequency of seizures

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: evaluate effect of ivermectin on frequency of seizures

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin
Description: evaluate effect of ivermectin on frequency of seizures
Study: NCT03030573

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Reconstruction of the bile duct with the round ligament
Description: In patients who had bile duct defect by injury or resection, the Round ligament will be used to reconstruct the defect. Surgical technique, the early and long term postoperative measures are detailed in the investigators protocol.
Study: NCT03853447

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic imaging
Description: MRI assessments including magnetic resonance cholangiopancreatography (MRCP) and diffusion weighted imaging (DWI) combined with gold standard EUS
Study: NCT00302042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief counseling plus group diabetes prevention in community
Description: Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk, Group diabetes prevention in community: 16 weekly group lifestyle behavior change visits followed by monthly group lifestyle behavior change visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Counseling for pre-diabetes alone
Description: Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk.
Study: NCT03669692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction
Description: Subjects will be trained to perform intermittent caloric restriction, based on an early time restricted feeding, with a 16/8 hour fasting / feeding schedule, respectively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Subjects will receive diet and lifestyle recommendations from the Spanish Association of Urology, for symptoms secondary to HBP, without restriction in the meal schedule.
Study: NCT02190227

Intervention type: DEVICE
Group type: OTHER
Intervention: Tumor RDA biopsy
Description: Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
Study: NCT04283162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Dobesilate
Description: use calcium dobesilate at the dosage of 500 mg, orally, 3 times per day, for 12 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: maintain lifestyle habits and the usual treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: maintain lifestyle habits and the usual treatment
Study: NCT03287167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 month DAPT
Description: Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on monotherapy with ASA only, unless contraindications for ASA emerge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 months DAPT
Description: Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 6 months, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
Study: NCT01837992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Study: NCT02311413

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
Study: NCT03810170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: safe sex and HIV/STD prevention education via a website
Description: website providing positive psychology-based advice and education for women over the age of 50 who are divorced. embedded in site is safe sex education.
Study: NCT01837992

Intervention type: DRUG
Group type: OTHER
Intervention: delayed primaquine
Study: NCT00183092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinacrine
Description: 100mg by mouth three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg by mouth three times a day
Study: NCT04001881

Intervention type: OTHER
Intervention: Transthoracic echocardiography
Description: A standard TTE protocol is used in all patients and included the following views: subcostal 4-chamber (SUBC), apical 4-chamber (4CH), apical 2-chamber (2CH), apical 3-chamber (3CH), parasternal long (LAX) and short axis (SAX).

Intervention type: OTHER
Intervention: Transthoracic echocardiography
Description: A standard TTE protocol is used in all patients and included the following views: subcostal 4-chamber (SUBC), apical 4-chamber (4CH), apical 2-chamber (2CH), apical 3-chamber (3CH), parasternal long (LAX) and short axis (SAX).

Intervention type: DRUG
Intervention: Spinal anesthesia
Description: Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.

Intervention type: DRUG
Intervention: Spinal anesthesia
Description: Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
Study: NCT02052232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental protein powder sachet
Description: mixed with 8 oz. water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control protein powder sachet
Description: mixed with 8 oz. water
Study: NCT01950533

Intervention type: PROCEDURE
Intervention: Oral food challenge
Description: Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.

Intervention type: PROCEDURE
Intervention: Oral food challenge
Description: Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.

Intervention type: PROCEDURE
Intervention: Oral food challenge
Description: Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.
Study: NCT03810170

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: written materials on safe sex
Description: 2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
Study: NCT03008174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early one-way speaking valve (OWSV) assessment
Description: The OWSV assessment by speech language pathologists will be completed at 12-24 hours following percutaneous tracheostomy procedure, which is earlier than the current standard of care of 48 hours or later.
Study: NCT03082144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
Study: NCT01465022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined estrogen-progestin pill
Description: 1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progestin-only pill
Description: .35 mg norethindrone once a day orally
Study: NCT01327300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
Study: NCT02524457

Intervention type: OTHER
Intervention: This is an observational study. There are no interventions

Intervention type: OTHER
Intervention: This is an observational study. There are no interventions
Study: NCT03492099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: Patients in this study will receive dosages to be determined by a physician that are specific to each patient.
Study: NCT02310464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-833/OBI-821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-833/OBI-821
Study: NCT04588987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1
Description: Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1
Description: Neoadjuvant PD-1 and Apatinib for rHGG. Adjuvant PD-1 and Apatinib for rHGG
Study: NCT04159233

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Behavioral Therapy for Insomnia (BBTI)
Description: Participants will receive evidence-based 'Brief Behavioral Therapy for Insomnia' (BBTI), tailored to meet the needs of former football players. BBTi is a brief, efficacious treatment that focuses on modifying behaviors, rather than cognitive domains. The treatment emphasizes education, motivational tools, and specific behavioral recommendations (e.g., restricting time in bed) and will be administered through weekly phone calls with a trained sleep interventionist over 4-weeks.
Study: NCT04475133

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ultrasound guided percutaneous neuromodulation
Description: It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous neuromodulation
Description: It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous neuromodulation
Description: It is a technique that consists in the electrical stimulation of peripheral nerve trunks, inserting an acupuncture needle in its path and using it as an electrode to apply electrical current
Study: NCT02746211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Titre Influenza virus
Description: High Titre Influenza virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium - High Influenza virus
Description: Medium - High Influenza virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium Low Titre Influenza virus
Description: Medium Low Titre Influenza virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low titre
Description: Low titre
Study: NCT01123109

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3-D Endoanal Ultrasound
Description: The subject will be placed in the supine position with their feet in the stirrups and a drape will be used, exposing only the anus and perineum in order to introduce the probe. In order to prevent and minimize any potential discomfort, the lubricated ultrasound probe will be gently inserted into the anal canal up to the anal verge, with minimal manipulation of the probe once inserted. The scan lasts approximately two minutes and the entire exam will take no more than five minutes.
Study: NCT01978665

Intervention type: DRUG
Group type: OTHER
Intervention: prednisone
Description: similar size tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Description: similar size tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Description: similar size tablets
Study: NCT00121641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Metformin
Description: Tablets, Oral, 0 mg, daily (42 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, 500-2000 mg (as needed for rescue)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Tablets, Oral, 500-2000 mg (as needed for rescue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, 500-2000 mg (as needed for rescue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, 500-2000 mg (as needed for rescue)
Study: NCT02676505

Intervention type: BEHAVIORAL
Intervention: Coached pushing group
Description: It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.

Intervention type: BEHAVIORAL
Intervention: uncoached pushing group
Description: It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
Study: NCT04354207

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral vein punction
Description: Vitamin D level, vitamin D receptor genetic polymorphisms, allergen specific IgE and total IgE will be measured in peripheral blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral vein punction
Description: Vitamin D level, vitamin D receptor genetic polymorphisms, allergen specific IgE and total IgE will be measured in peripheral blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral vein punction
Description: Vitamin D level, vitamin D receptor genetic polymorphisms, allergen specific IgE and total IgE will be measured in peripheral blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool collection
Description: Gut microbiome will be investigated in stool samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool collection
Description: Gut microbiome will be investigated in stool samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool collection
Description: Gut microbiome will be investigated in stool samples.
Study: NCT02524457

Intervention type: OTHER
Intervention: This is an observational study. There are no interventions
Study: NCT03302676

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chewing gum
Study: NCT03475992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-power microwave breast imaging system
Description: Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-power microwave breast imaging system
Description: Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump
Study: NCT02607436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate
Description: Sarpogrelate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin